Clinician-context pageThis topic can involve test or imaging interpretation, neurological disease, surgery, medication, or complex underlying conditions. BioConst keeps this page as an explainer, not a decision guide.
What this means
Fibrous dysplasia replaces normal bone and marrow with fibro-osseous tissue in focal or multiple lesions.[1,2]
What people may notice
- It can range from an incidental single lesion to widespread disease with pain, deformity, fracture risk, mobility loss, or craniofacial effects.[1]
- It can occur alone or as part of McCune-Albright syndrome with skin and endocrine findings.[2]
- Lesion location matters more than a whole-body density label.[1]
Key variables
X-rayImaging maps lesion location and structure.[1]
PhosphateSome FD/MAS contexts include phosphate wasting and mineralization issues.[1]
Why it happens
- FD/MAS is a mosaic disorder associated with post-zygotic GNAS activation.[1]
- Mosaicism explains why lesions can be patchy and severity variable.[1]
- Endocrine overactivity can change the bone story in McCune-Albright context.[1]
Clinical response directions
- Clinical teams may use imaging surveillance, pain/function management, fracture/deformity care, and endocrine evaluation.[1]
- Craniofacial, endocrine, and phosphate-wasting contexts can require specialized review.[1]
- BioConst does not interpret lesion progression or surgery decisions.[1]
Common traps
- This is not ordinary low bone density.[1]
- A single lesion and polyostotic disease are very different practical situations.[1]
- Endocrine findings can be part of the bone story.[2]